Exploring Gilead Sciences, Inc. (GILD) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind Gilead Sciences, Inc. (GILD), and what drives their investment decisions? With institutional investors holding approximately 85.10% of the company's shares, and retail investors owning about 13.79%, understanding the investor profile can provide valuable insights into the company's stability and future prospects. Are these investors primarily focused on long-term growth, or are they driven by short-term gains? Let's delve into the details of who is investing in Gilead, and the factors influencing their choices, considering that in 2024, Gilead's revenue reached $28.75 billion, marking a 6.04% increase from the previous year.

Gilead Sciences, Inc. (GILD) Who Invests in Gilead Sciences, Inc. (GILD) and Why?

Understanding the investor profile of Gilead Sciences, Inc. (GILD) provides valuable insights into market sentiment and the factors driving investment decisions. The company's stock is held by a diverse range of investors, each with their own motivations and strategies.

Key Investor Types:

Gilead Sciences, Inc. (GILD) attracts a mix of retail and institutional investors. Here's a breakdown:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. They may be attracted to Gilead Sciences, Inc. (GILD) due to its dividend yield or perceived long-term growth potential.
• Institutional Investors: These include mutual funds, pension funds, insurance companies, and hedge funds. Institutional investors often hold a significant portion of Gilead Sciences, Inc. (GILD)'s outstanding shares.
• Hedge Funds: These are typically more active investors who may take larger positions and employ various trading strategies to generate returns.

Investment Motivations:

Several factors attract investors to Gilead Sciences, Inc. (GILD):

• Growth Prospects: Investors are drawn to Gilead Sciences, Inc. (GILD)'s pipeline of potential new drugs and therapies, particularly in areas like oncology and virology. Positive clinical trial results and regulatory approvals can drive investor interest.
• Dividends: Gilead Sciences, Inc. (GILD) pays a dividend, which can be attractive to income-seeking investors. A stable or growing dividend can provide a steady stream of income.
• Market Position: Gilead Sciences, Inc. (GILD) has a strong market position in certain therapeutic areas, such as HIV treatment. This established presence can provide a degree of stability and predictability.
• Value Proposition: Some investors may view Gilead Sciences, Inc. (GILD) as undervalued based on its financial metrics, such as price-to-earnings ratio or free cash flow. This can lead to value investing strategies.

Investment Strategies:

Investors in Gilead Sciences, Inc. (GILD) employ various strategies:

• Long-Term Holding: Many institutional investors, such as mutual funds and pension funds, adopt a long-term holding strategy. They believe in the company's long-term potential and hold shares for extended periods.
• Short-Term Trading: Hedge funds and other active traders may engage in short-term trading strategies to profit from price fluctuations. These strategies can involve technical analysis and event-driven trading.
• Value Investing: Value investors seek to identify undervalued companies and hold their shares until the market recognizes their true worth. They may focus on Gilead Sciences, Inc. (GILD)'s financial statements and intrinsic value.
• Growth Investing: Growth investors focus on companies with high growth potential. They may be attracted to Gilead Sciences, Inc. (GILD)'s pipeline of new drugs and therapies.

To delve deeper into Gilead Sciences, Inc. (GILD)'s financial standing, explore: Breaking Down Gilead Sciences, Inc. (GILD) Financial Health: Key Insights for Investors

Gilead Sciences, Inc. (GILD) Institutional Ownership and Major Shareholders of Gilead Sciences, Inc. (GILD)

Institutional ownership in Gilead Sciences, Inc. (GILD) reflects the degree of confidence and influence large financial entities have in the company. These institutions, which include mutual funds, pension funds, and hedge funds, manage substantial assets and their investment decisions can significantly impact Gilead's stock price and overall market strategy.

As of December 31, 2024, the top institutional holders of Gilead Sciences, Inc. (GILD) include:

• Vanguard Group Inc holds 94,663,734 shares, representing 7.55% ownership.
• BlackRock Fund Advisors holds 65,964,794 shares, representing 5.26% ownership.
• State Street Global Advisors, Inc. holds 47,229,144 shares, representing 3.77% ownership.
• Geode Capital Management LLC holds 14,994,742 shares, representing 1.20% ownership.
• Northern Trust Investments, Inc. holds 14,217,149 shares, representing 1.13% ownership.

Examining recent changes in ownership provides insights into the evolving sentiment of institutional investors. Monitoring these shifts can indicate whether large investors are increasing their stakes, signaling confidence in the company's future, or decreasing their positions, which might suggest concerns about performance or market conditions.

Recent ownership trends reveal the following adjustments:

• Vanguard Group Inc decreased their holdings by -2,428,474 shares.
• BlackRock Fund Advisors increased their holdings by 449,438 shares.
• State Street Global Advisors, Inc. increased their holdings by 1,524,983 shares.
• Geode Capital Management LLC increased their holdings by 1,139,362 shares.
• Northern Trust Investments, Inc. increased their holdings by 448,722 shares.

Institutional investors play a crucial role in Gilead Sciences, Inc. (GILD)'s stock price and strategic direction. Their investment decisions can drive significant trading volume and influence market perception. For example, a large purchase by a major institutional investor can lead to an increase in stock price, while a significant sell-off can have the opposite effect.

Here is a detailed breakdown of the top institutional investors and their holdings in Gilead Sciences, Inc. (GILD) as of the end of 2024:

For additional insights into Gilead Sciences, Inc. (GILD)'s financial standing, consider exploring: Breaking Down Gilead Sciences, Inc. (GILD) Financial Health: Key Insights for Investors

Gilead Sciences, Inc. (GILD) Key Investors and Their Impact

Understanding the investor profile of Mission Statement, Vision, & Core Values of Gilead Sciences, Inc. (GILD). is crucial for assessing the company's stability, growth potential, and overall market sentiment. Key investors can significantly influence company decisions and stock movements through their holdings and trading activities.

As of April 2025, 3111 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities and Exchange Commission (SEC), holding a total of 1,320,765,437 shares. This indicates a strong institutional presence in Gilead Sciences, Inc. (GILD).

The ownership structure of Gilead Sciences, Inc. (GILD) stock is a mix of institutional, retail, and individual investors. Approximately 58.34% of the company's stock is owned by Institutional Investors, 0.09% is owned by Insiders, and 41.56% is owned by Public Companies and Individual Investors.

Here's a breakdown of the major shareholders:

• BlackRock, Inc.: Holds 9.66% of the company, with 120,355,841 shares valued at approximately $12.82 billion.
• Vanguard Group Inc.: Holds 9.28% of the company, with 115,528,392 shares, worth around $12.30 billion.
• Capital World Investors: Possesses 5.76% of the company, with 71,706,362 shares, valued at $7.64 billion.
• State Street Corp: Owns 4.85% of the company, with 60,381,755 shares, amounting to $6.43 billion.
• Capital Research Global Investors: Holds 4.65% of the company, with 57,946,228 shares, worth $6.17 billion.
• Fmr LLC: Has a 3.24% stake in the company, with 40,319,432 shares, valued at $4.29 billion.
• Wellington Management Group LLP: Controls 2.86% of the company, with 35,659,007 shares, totaling $3.80 billion.
• Dodge & Cox: Holds 2.65% of the company, with 32,947,717 shares, worth $3.51 billion.
• Geode Capital Management LLC: Owns 2.27% of the company, with 28,289,917 shares, valued at $3.01 billion.
• Morgan Stanley: Has a 1.61% stake in the company, with 20,070,463 shares, amounting to $2.14 billion.

These major institutional investors can significantly impact Gilead Sciences, Inc. (GILD)'s stock price and corporate governance. Their investment decisions often reflect their confidence in the company's future prospects.

Recent activity in Q4 2024 shows that several institutional investors have made significant changes to their positions:

• BANK OF AMERICA CORP /DE/: Increased its holdings by 10,487,673 shares (+145.1%), with an estimated value of $968,746,355.
• FMR LLC: Added 7,157,113 shares (+21.6%), valued at approximately $661,102,527.
• PACER ADVISORS, INC.: Increased its stake by 5,653,075 shares (+723.3%), with an estimated value of $522,174,537.

Conversely, some institutions have reduced their positions, indicating a mixed sentiment among investors.

Recent insider trading activity reveals that insiders have been primarily selling shares. For example, Andrew D. Dickinson (Chief Financial Officer) sold 564,930 shares for an estimated $54,892,531 over the last six months. Merdad Parsey (Chief Medical Officer) sold 189,801 shares for approximately $17,435,498 during the same period.

Members of Congress have also been active in trading Gilead Sciences, Inc. (GILD) stock, with recent purchases including:

• Representative Jefferson Shreve purchased up to $50,000 on March 31.
• Representative Carol D. Miller purchased up to $15,000 on March 10.
• Representative Josh Gottheimer purchased up to $15,000 on March 7.
• Representative Marjorie Taylor Greene purchased up to $15,000 on December 24.

These transactions reflect a diverse range of perspectives on Gilead Sciences, Inc. (GILD)'s potential, from both within and outside the company.

Gilead Sciences, Inc. (GILD) has a large analyst coverage. In the last 6 months, 5 analysts have offered price targets for Gilead Sciences, Inc. (GILD), with a median target of $126.0. Recent targets include:

• Terence Flynn from Morgan Stanley set a target price of $130.0 on March 11, 2025.
• An analyst from Johnson Rice set a target price of $126.0 on March 5, 2025.
• An analyst from Oppenheimer set a target price of $132.0 on March 4, 2025.
• Brian Abrahams from RBC Capital set a target price of $83.0 on January 7, 2025.
• Joseph Catanzaro from Piper Sandler set a target price of $105.0 on November 7, 2024.

These analyst ratings provide additional context for investors, although they should not be the sole basis for investment decisions.

The following table summarizes the ownership details of Gilead Sciences, Inc. (GILD) as of December 31, 2024:

Overall, institutional investors have a significant ownership stake in Gilead Sciences, Inc. (GILD), which can lead to both stability and potential volatility in the stock price. Monitoring the activities of these key investors can provide valuable insights into the future direction of the company.

As of April 17, 2025, the share price was $104.54. Previously, on April 19, 2024, the share price was $66.76. This represents an increase of 56.59% over that period.

The current share price of Gilead Sciences Inc. is $104.99, reflecting a -1.42% change over the last 24 hours.

The stock information overview is:

• Price: $104.54
• Volume: 8,066,776
• Change: -0.34
• % Change: -0.32%
• Today's Open: $104.74
• Previous Close: $104.88
• Intraday High: $105.75
• Intraday Low: $103.52
• 52 Week High: $119.96
• 52 Week Low: $62.07

Key Data includes:

• 1 Year Target: $110.00
• Today's High/Low: $105.2250/$103.0900
• Share Volume: 6,720,995
• Average Volume: 9,744,075
• Previous Close: $104.54
• Market Cap: 129,926,954,648
• Forward P/E 1 Yr: 13.30
• Special Dividend Date: March 14, 2025
• Special Dividend: $0.79
• Special Dividend Pay Date: March 28, 2025

On Monday, Gilead Sciences Inc (GILD:NSQ) closed at 104.29, -13.06% below its 52-week high of 119.96, set on Mar 10, 2025.

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Institutional investors own 86%.

BlackRock Inc is the largest individual Gilead Sciences shareholder, owning 120.36M shares representing 9.66% of the company. Blackrock Inc's Gilead Sciences shares are currently valued at $12.72B.

Institutional Ownership is 85.30%

Total Shares Outstanding (millions) 1,247.

Total Value of Holdings (millions) $111,171.

85.10% institutional shareholders, 1.11% Gilead Sciences insiders, and 13.79% retail investors.

Institutional Sellers (last 12 months): 957.

Total Institutional Outflows (last 12 months): $7.82B.

We have seen 803 institutional investors add shares of GILD stock to their portfolio, and 837 decrease their positions in their most recent quarter.

GILD insiders have traded GILD stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.

Members of Congress have traded GILD stock 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here's a breakdown of recent trading of $GILD stock by insiders over the last 6 months:

• ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 11 sales selling 564,930 shares for an estimated $54,892,531.
• MERDAD PARSEY (Chief Medical Officer) has made 0 purchases and 7 sales selling 189,801 shares for an estimated $17,435,498.
• JEFFREY BLUESTONE sold 6,788 shares for an estimated $620,355.

Here's a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:

• REPRESENTATIVE JEFFERSON SHREVE purchased up to $50,000 on 03/31.
• REPRESENTATIVE CAROL D. MILLER purchased up to $15,000 on 03/10.
• REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 03/07.
• REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 12/24.

Insider Trade:

• 3 Months:
• Number of Shares Bought: 412,577
• Number of Shares Sold: 523,580
• Total Shares Traded: 936,157
• Net Activity: (111,003)
• 12 Months:
• Number of Shares Bought: 424,127
• Number of Shares Sold: 1,090,799
• Total Shares Traded: 1,514,926
• Net Activity: (666,672)

Gilead Sciences, Inc. (GILD) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to key players is crucial for assessing the potential trajectory of Gilead Sciences, Inc. (GILD). This analysis delves into the current investor sentiment, recent market reactions, and analyst perspectives to provide a comprehensive overview.

Investor Sentiment:

Currently, institutional investors heavily dominate Gilead Sciences, Inc., owning approximately 86% of the shares. This substantial holding implies that institutions have significant influence over the company's share price. As of December 31, 2024, the largest shareholders include:

• BlackRock, Inc.: 120,355,841 shares
• Vanguard Group Inc.: 115,528,392 shares
• Capital World Investors: 71,706,362 shares
• State Street Corp.: 60,381,755 shares
• Capital Research Global Investors: 57,946,228 shares
• Fmr Llc: 40,319,432 shares
• Wellington Management Group Llp: 35,659,007 shares
• Dodge & Cox: 32,947,717 shares
• Geode Capital Management, Llc: 28,289,917 shares
• Morgan Stanley: 20,070,463 shares

Recent data indicates mixed sentiment among major shareholders. For instance, BlackRock, Inc. reduced its holdings by 1,579,953 shares, while Vanguard Group Inc. increased its position by 185,508 shares as of December 31, 2024.

Overall institutional ownership stands at 85.30%, with a total value of holdings amounting to $111,171 million as of December 31, 2024. This indicates strong institutional confidence in Gilead Sciences.

Recent Market Reactions:

The stock market's reaction to changes in ownership and large investor moves has been notable. On April 9, 2025, Gilead Sciences' stock price dropped by 4.83% in pre-market trading, reflecting a decline in investor sentiment attributed to market volatility and regulatory pressures.

However, Gilead Sciences has shown resilience. In 2024, the company's shares gained 15.4%, outperforming the industry's decline of 10.8%. This positive performance was driven by new drug approvals, encouraging pipeline progress, positive data readouts, and strong quarterly results. The company also raised its annual guidance for sales and earnings, driven by growth in COVID-19 treatment Veklury sales.

As of April 17, 2025, the share price was $104.54, a 56.59% increase from $66.76 on April 19, 2024.

Analyst Perspectives:

Analysts' perspectives on Gilead Sciences' future are varied, with ratings ranging from bullish to bearish. A consensus of 38 analysts gives Gilead Sciences a 'Buy' rating, with a price prediction of $100.50 for 2025.

Key points from analyst evaluations include:

• The average 12-month price target is $109.90, suggesting a potential upside of 5.13% from the current share price.
• Gilead Sciences' earnings are expected to grow significantly. The forecast annual earnings growth rate of 186.75% is projected to beat the US Drug Manufacturers - General industry average of 46.57%.
• Revenue for 2025 is forecasted to be $35.67 billion.
• Earnings per share (EPS) for 2025 is expected to be $7.87, a 70% increase compared to the previous year.

However, some analysts have lowered their price targets, reflecting concerns about market dynamics and specific challenges. For example, in April 2024, several analysts lowered their ratings, citing various factors influencing their evaluations.

Financial Performance and Forecasts:

Gilead Sciences' financial performance in 2024 showed a revenue of $28.75 billion, a 6.04% increase from the previous year. However, earnings decreased by -91.53% to $480.00 million.

Looking ahead, analysts predict varied stock prices for Gilead Sciences:

These forecasts suggest potential fluctuations in the stock price, influenced by market conditions and company-specific developments.

Additional Factors:

• Gilead's operational efficiency is expected to drive earnings growth, with annual earnings projected to soar by 70% in FY25.
• The company's attractive dividend yield, currently at 2.65%, is a positive factor for investors.
• Gilead's focus on core strengths in viral diseases, inflammatory and fibrotic diseases, and oncology remains a key driver for long-term growth.

For further insights into Gilead Sciences' financial health, explore: Breaking Down Gilead Sciences, Inc. (GILD) Financial Health: Key Insights for Investors